The mission of the Southwest Oncology Group (SWOG) is to conduct clinical trials to prevent and treat cancer in adults, and to improve the quality of life for cancer survivors. The mission is accomplished through the mutual efforts ofthe Group Chair's Office, the Operations Office, the Statistical Center and the dedicated oncology professionals in the institutions of the Group. The Statistical Center contributes to the mission of the Group though the following key activities: 1) Participation in protocol development, emphasizing statistically sound study designs;2) Collection, review, manage and store data from Group studies, and to follow sound quality control procedures which ensure the integrity of data evaluations;3) Development and maintenance of electronic applications to support the research and goals of the Southwest Oncology Group, including data collection, data management, data retrieval and analysis;4) Analysis, interpretation and publication of results from ail Southwest Oncology Group studies;5) Performance of methodologic research to address ongoing design and analysis issues important to the conduct of cancer clinical trials and to ancillary biologic studies;6) Participation in training of new Clinical Research Associates (CRAs) and of Young Investigators in the Group. Biostatisticians and Data Coordinators educate investigators, nurse oncologists and CRAs in statistical analysis, research design and the utilization of the most advanced scientific and data management strategies;and 7) Collaboration with the Group Chair and other investigators in the Group to improve the quality of clinical trials through the use of improved data collection forms, reproducible data definitions and economical data flow, and efficient use of Statistical Center resources.
Clinical trials are the best mechanism for improving the outcomes of therapy for cancer, increasing the chance for cure and the probability that future patients will be given appropriate care. The SWOG Statistical Center contributes to this process through the efficient and high-quality design, management, and analysis of these trials, thereby helping to ensure that the results of clinical trials are generalizable and reproducible.
|Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-40|
|Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62|
|Walter, R B; Othus, M; Burnett, A K et al. (2015) Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 29:312-20|
|Unger, Joseph M; Barlow, William E; Martin, Diane P et al. (2014) Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst 106:dju002|
|Coutre, Steven E; Othus, Megan; Powell, Bayard et al. (2014) Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol 165:497-503|
|Dhodapkar, Madhav V; Sexton, Rachael; Waheed, Sarah et al. (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85|
|Twardowski, Przemyslaw W; Mack, Philip C; Lara Jr, Primo N (2014) Papillary renal cell carcinoma: current progress and future directions. Clin Genitourin Cancer 12:74-9|
|NSCLC Meta-analysis Collaborative Group (2014) Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 383:1561-71|
|Henry, N Lynn; Henry, Lynn N; Hayes, Daniel F et al. (2014) Promoting quality and evidence-based care in early-stage breast cancer follow-up. J Natl Cancer Inst 106:dju034|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
Showing the most recent 10 out of 451 publications